## Special Issue

# Cutaneous Lymphomas: From Pathology to Treatment

## Message from the Guest Editors

Cutaneous T cell lymphomas (CTCL) are a rare subtype of non-Hodgkin lymphoma and a malignancy of skinhoming T cells. CTCL presents primarily in the skin at the time of diagnosis. Mycosis fungoides, the variants of mycosis fungoides, and Sezary syndrome (MF/SS) are the most common types, accounting for approximately 60% of all CTCLs. In recent years, remarkable progress has been made in the field of CTCL. The revision of classification has contributed to a more precise diagnosis, prognosis, and treatment of CTCL. A deeper understanding of the functions of epigenetic modulation and tumor microenvironment has opened avenues for the discovery of novel therapies and the development of strategies to overcome drug resistance. Moreover, gaining insights into the mechanisms of action and treatment responses of novel agents, with the identification of prognostic biomarkers, is propelling us toward a more personalized therapeutic approach. For this Special Issue of *Cancers*, we welcome original research and review articles that encompass the recent advances and address the future challenges in the diagnosis, biological insights, and treatment of CTCL.

#### **Guest Editors**

Dr. Weivun Z. Ai

Department of Medicine, Divison of Hematology and Oncology, University of California, San Francisco, CA, USA

Dr. Christiane Querfeld

Division of Dermatology, City of Hope, Duarte, CA 91010, USA

## Deadline for manuscript submissions

closed (30 June 2025)



## **Cancers**

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/196316

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers





## **Cancers**

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



## **About the Journal**

## Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

#### **Editor-in-Chief**

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

### **Author Benefits**

## **Open Access:**

free for readers, with article processing charges (APC) paid by authors or their institutions.

## **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

